retatrutide trial results news today This is exciting. 👀 The TRIUMPH-4 for Lilly's investigational medication were released, showing weight loss of up to 71 lbs (~28%) over 68 weeks in the highest-dose group—far beyond An experimental weight-loss drug from

Be sure to eat regular meals and stay hydrated

Prescribing information (Amneal Pharmaceuticals, 2025)

In contrast, GLP-1 receptor agonists approved by the FDAincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound, which also activates GIP receptors)are modified to resist DPP-4 degradation

Keerie, A

Decisions here should be individualized and involve the prescribing clinician

What makes Sofwave particularly relevant for GLP-1 patients is its ability to address skin laxity across multiple areas: the face, neck, jawline, arms, abdomen, and thighs